Cambridge Day: Health care costs keep rising, but biopharma is not the enemy
Cambridge is home to the world's most innovative biotech companies. Resident Neil Kairen explains the importance of this industry and suggests explanations for why so many misunderstand its value.
Bucks County Herald: Drug price controls hurt investment in new medicines
Researchers in Pennsylvania are working on a cure for Parkinson’s. Price controls threaten their progress.
Fairfax Connection: Our Neighborhood’s Special Role in Saving Babies from Norovirus
A company in Virginia is working on a vaccine to protect babies from rotavirus and norovirus.
RealClearHealth: For Two Years, Australia Failed People With Cystic Fibrosis; It Can’t Happen Again
Governments around the world have withheld access to life-changing medications for people with cystic fibrosis (CF) for years in the name of being hawkish on drug pricing.
Timmerman Report: Aducanumab & the Alzheimer’s Moonshot: What Would It Be Worth to Keep Your Mind?
Alzheimer’s and diseases like it have horrible costs on individuals, caregivers, and their families. A treatment for Alzheimer’s would not only relieve suffering for the patient and their family, but it would increase the productivity of millions of Americans and lower direct and indirect costs associated with care. And, once the treatment becomes generic, it will permanently upgrade human health for much less.